Health Trials

B7H3

2

Review clinical trials related to B7H3. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).

Participants needed: 138
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Aktis Oncology, Inc.Updated: May 12, 2026Locations: 2
Eligibility criteria

Age ≥ 18 years [+8]

Prior treatment with more than 2 Androgen receptor pathway inhibitors (ARPIs) an... [+5]

Read more
Status: Recruiting

Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors

Based on \[68Ga\]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression. Utilizing whole-body PET technology, the pharmacokinetic dynamics of \[68Ga\]B7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics. Ultimately, this research establishes a framework for pharmacokinetic analysis using whole-body PET.

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Aug 23, 2024Locations: 1
Eligibility criteria

Age range 18-75 years, open to both male and female participants; [+8]

Severe abnormalities in liver and renal function and blood counts; [+6]

Read more